Phase 1 and Phase 2. Normally a Phase 1 trial uses healthy volunteers. Given the invasiveness of the procedure and the fact that the goal is regeneration, it doesn't make sense to use healthy volunteers. The first 3 people in the trial were essential a safety cohort. That is, as I understand it, the first part of the Phase 1 component of the trial.When they say phase 1/2 trial do they mean they're in phase 1 AND 2 or Phase 1 OF 2?
After the safety cohort, they began varying the doses. This is second part of the Phase 1 part of the trial. In other words, the main goal here is safety though they would of course monitor outcomes. Unless something has changed, there are to be 4 cohorts of 3 people. (I believe it was during this part of the trial when the trial was paused.)
Finally, there is the Phase 2 part of the trial with 20 patients. The dose is presumably based on the second part of the Phase 1 component. This is the efficacy phase. There is no placebo arm of the trial.
Thus the total size is 45 people. As of early February, they had enrolled 11 patients. It's not clear how soon we will know any actual results of the trial. If we have to wait for them to enroll 45 people, we seemingly have a long way to go.
I called the lady working on the study. They are starting the phase now and still asking for people. I asked her when will they know the results and she said by the end of the year.
Not sure what results you or she meant. It is possible some results will be released by the end of the year, but given the difficulty they are apparently having with enrolling patients, it seems very unlikely that the final results will be available for some time.
Member
If you ring the centres and ask about results they think you are a broker and try and wind up the call. They have been briefed on the importance of data protection. There will be a lot of jealous investigators if Staecker comes up with the goods. I see Albert Edge is now launching a similar human phase 1 for end of summer 2019, he was all mouse and gerbils till he saw cgf roll past him. Interesting how when one lab makes a move the others panic and rush to human trials. A lot of these drs have their own cash in their own projects, Swirsky himself has put an absolute fortune into genvec from his own pocket, details like that matter a LOT.